Patents by Inventor Robert McKay
Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7897583Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPRU in a cell, tissue or animal. Also provided are methods of active target segment validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hyperfattyacidemia, liver steatosis, steatohepatitis, non-alcoholic steatohepatitis, metabolic syndrome, cardiovascular disease and coronary heart disease by administration of antisense compounds targeted to PTPRU.Type: GrantFiled: May 24, 2006Date of Patent: March 1, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: Robert McKay, Ravi Jain, Kenneth W. Dobie, Sanjay K. Pandey, Sanjay Bhanot
-
Patent number: 7884086Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.Type: GrantFiled: September 7, 2005Date of Patent: February 8, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
-
Publication number: 20100311824Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box 01A are provided, in particular, for methods of treating diabetes.Type: ApplicationFiled: August 20, 2010Publication date: December 9, 2010Applicant: ISIS PHARMACEUTICALS, INC.Inventors: KENNETH W. DOBIE, SANJAY BHANOT, ROBERT MCKAY, SANJAY K. PANDEY
-
Patent number: 7807649Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: April 23, 2007Date of Patent: October 5, 2010Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
-
Patent number: 7802655Abstract: A solid composition stick applicator is provided. The applicator comprises an applicator body having a first and second end, the second end having an opening through which a solid composition stick is dispensed. Within the applicator is housed a helical tension spring having a first spring end and a second spring end, the first spring end, second spring end, or both the first and second spring end held at a fixed position with respect to the applicator body. The helical tension spring is wound around a guide system that is housed within the applicator body. A pushing assembly is attached to the helical tension spring and the pushing assembly is movable from a first position at or near the first end of the applicator body, to a second position at or near the second end of the applicator body. Tension within the helical tension spring is greater in the first position than in the second position thereby urging the pushing assembly towards the second end of the applicator body.Type: GrantFiled: September 8, 2004Date of Patent: September 28, 2010Assignee: Kelsan Technologies Corp.Inventors: Jonathan de Wet, Ron C. Y. Hui, Douglas Robert McKay, Zdravko Zdjelar, Robert J. Harris
-
Publication number: 20100222412Abstract: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for treatment of diseases are provided.Type: ApplicationFiled: January 14, 2010Publication date: September 2, 2010Applicant: Isis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Robert McKay, Susan M. Freier, Sanjay Bhanot, Lynnetta Watts
-
Publication number: 20090326041Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 31, 2009Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20090325615Abstract: Methods, systems, and software for mediating SMS messages, and especially type 0 SMS messages, in a wireless mobile communications device configured to send and receive data using a GSM protocol and including a subscriber identity module (“SIM”) including electronic hardware and computer software executed by the hardware such that the SIM is configured to send, receive, and process messages using a Short Message System (“SMS”) between the wireless mobile communications device and a communications network. One aspect includes a method for mediating SMS messages comprising: configuring electronic hardware on the wireless mobile communications device to implement a firewall on the wireless mobile communications device, the firewall configured to identify and optionally mediate infrastructure SMS messages.Type: ApplicationFiled: June 28, 2009Publication date: December 31, 2009Applicant: Oceans' Edge, Inc.Inventors: Robert McKay, Sam Emara, Steven Hildner, Thomas Shanley, Wesley Driver, Jay Lukin, Terry Bahr, Tim Berzins, Mihaela Mihaylova, Nathan Klonoski
-
Publication number: 20090326042Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 31, 2009Applicant: Isis Pharmaceuticals, IncInventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewitz
-
Publication number: 20090318532Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 24, 2009Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20090306357Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 10, 2009Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20090306179Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 10, 2009Applicant: ISIS Pharmaceuticals Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20090306005Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 10, 2009Applicant: Isis Phamaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
-
Publication number: 20090306180Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: December 10, 2009Applicant: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert Mckay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20090292006Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: May 7, 2007Publication date: November 26, 2009Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20090258931Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.Type: ApplicationFiled: February 19, 2009Publication date: October 15, 2009Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
-
Publication number: 20090221671Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.Type: ApplicationFiled: May 24, 2006Publication date: September 3, 2009Inventors: Sanjay Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
-
Publication number: 20090200902Abstract: A portable workstation includes wheels, a tabletop, a generally planar member and a chassis joining the wheels, the tabletop and the planar member. While joined to the wheels and the tabletop by the chassis, the planar member is movable between a protracted position and a retracted position. A majority of the planar member extends above the tabletop in the protracted position, and a majority of the planar member does not extend above the tabletop in the retracted position.Type: ApplicationFiled: April 24, 2009Publication date: August 13, 2009Applicant: BRADYQUIN, LLCInventors: Jodi McKay, Ian D. Kovacevich, Thomas James Philpott, Robert McKay, Brett Rhinehardt, Daniel Lee Bizzell
-
Patent number: 7563884Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.Type: GrantFiled: December 9, 2004Date of Patent: July 21, 2009Assignee: Isis Pharmaceuticals, Inc.Inventors: Lex M. Cowsert, Jacqueline R. Wyatt, Susan M. Freier, Brett P. Monia, Madeline M. Butler, Robert McKay
-
Publication number: 20090124009Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.Type: ApplicationFiled: March 11, 2008Publication date: May 14, 2009Applicant: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie